RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide

Condition(s) studied

Investigational drug(s) / intervention(s)

NETest: Non-invasive blood test

Study summary

Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems. Treatment options include surgery, medical and ablative therapies as well as peptide-receptor radionuclide therapy. Survival is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. One challenge is to develop accurate non-invasive blood tests that can detect neuroendocrine tumor activity. A second challenge is to evaluate the effectiveness of molecular biomarkers in the natural history of this disease. RegisterNET registry aims at collecting data and blood samples from patients presenting with a NET. Data will be entered prospectively and anonymized after informed consent. All physicians who treat neuroendocrine tumor patients are invited to participate to the registry through prospective agreements and sub-study protocols with Wren Laboratories. Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types and grades of tumors, treatment modalities and patient outcomes (e.g. disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.

Eligibility

Primary outcome measure(s)

• Tumor-related recurrence or progression — 5 years
  Image-based identification of recurrent or progressive tumor disease
• Tumor-related diagnosis — 1 year
  Histological confirmation of neuroendocrine tumor
• Tumor-related mortality — 10 years
  Survival from disease

Trial sites (1)

More Wren Laboratories LLC trials in the USA

Other trials for the same condition